0000899243-23-004233.txt : 20230207
0000899243-23-004233.hdr.sgml : 20230207
20230207183501
ACCESSION NUMBER: 0000899243-23-004233
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230202
FILED AS OF DATE: 20230207
DATE AS OF CHANGE: 20230207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Violin Jonathan
CENTRAL INDEX KEY: 0001730615
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36483
FILM NUMBER: 23596530
MAIL ADDRESS:
STREET 1: 955 CHESTERBROOK BOULEVARD
STREET 2: SUITE 200
CITY: CHESTERBROOK
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE
CENTRAL INDEX KEY: 0001590750
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 471187261
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
BUSINESS PHONE: 617.272.4600
MAIL ADDRESS:
STREET 1: 203 CRESCENT STREET
STREET 2: BLDG. 17, SUITE 102B
CITY: WALTHAM
STATE: MA
ZIP: 02453
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: SIGNAL GENETICS, INC.
DATE OF NAME CHANGE: 20140710
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2023-02-02
2023-02-07
1
0001590750
Viridian Therapeutics, Inc.\DE
VRDN
0001730615
Violin Jonathan
C/O VIRIDIAN THERAPEUTICS, INC.
221 CRESCENT STREET, SUITE 401
WALTHAM
MA
02453
1
1
0
0
Chief Executive Officer
Common Stock
2023-02-02
4
M
0
50000
0.15
A
530905
D
Common Stock
2023-02-02
4
S
0
50000
36.80
D
480905
D
Stock Option (Right to Buy)
0.15
2023-02-02
4
M
0
50000
0.00
D
2030-09-23
Common Stock
50000
239205
D
Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold.
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
/s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
2023-02-07